On Monday, Humacyte Inc (NASDAQ: HUMA) opened lower -3.60% from the last session, before settling in for the closing price of $1.11. Price fluctuations for HUMA have ranged from $1.06 to $6.77 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 42.43% over the last five years. Company’s average yearly earnings per share was noted 76.74% at the time writing. With a float of $163.06 million, this company’s outstanding shares have now reached $193.00 million.
Humacyte Inc (HUMA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 15.51%, while institutional ownership is 23.96%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.21 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.25) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.26% during the next five years compared to 42.43% growth over the previous five years of trading.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 131.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Analysing the last 5-days average volume posted by the [Humacyte Inc, HUMA], we can find that recorded value of 5.86 million was better than the volume posted last year of 4.35 million. As of the previous 9 days, the stock’s Stochastic %D was 13.08%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 0.59%, which indicates a significant decrease from 3.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0807 in the past 14 days, which was lower than the 0.1264 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3938, while its 200-day Moving Average is $1.8668. Now, the first resistance to watch is $1.1333. This is followed by the second major resistance level at $1.1967. The third major resistance level sits at $1.2333. If the price goes on to break the first support level at $1.0333, it is likely to go to the next support level at $0.9967. Should the price break the second support level, the third support level stands at $0.9333.
Humacyte Inc (NASDAQ: HUMA) Key Stats
There are currently 187,271K shares outstanding in the company with a market cap of 206.51 million. Presently, the company’s annual sales total 0 K according to its annual income of -148,700 K. Last quarter, the company’s sales amounted to 750 K and its income totaled -17,510 K.
